Overview

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Status:
Completed

Trial end date:
2020-09-03

Target enrollment:

Participant gender:

Summary

This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.

Phase:

N/A

Details

Lead Sponsor:

Philip Philip

Collaborator:

National Cancer Institute (NCI)

Treatments:

Aprepitant
Fosaprepitant